|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication显示文摘 | Stéphanie Faure Astrid Herrero Boris Jung Yohan Duny Jean-Pierre Daures Thibaut Mura Eric Assenat Micha?l Bismuth Hassan Bouyabrine Hélène Donnadieu-Rigole Francis Navarro Samir Jaber Dominique Larrey Georges-Philippe Pageaux | 2012 | Journal of Hepatology2012，，2： | 1 |
| 2 | A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial显示文摘 | Marc Ychou Michel Rivoire Simon Thezenas Fran?ois Quenet Jean-Robert Delpero Christine Rebischung Christian Letoublon Rosine Guimbaud Eric Francois Michel Ducreux Fran?oise Desseigne Jean-Michel Fabre Eric Assenat | 2013 | Annals of Surgical Oncology2013，，13： | 1 |
| 3 | Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication显示文摘 | Stéphanie Faure Astrid Herrero Boris Jung Yohan Duny Jean-Pierre Daures Thibaut Mura Eric Assenat Micha?l Bismuth Hassan Bouyabrine Hélène Donnadieu-Rigole Francis Navarro Samir Jaber Dominique Larrey Georges-Philippe Pageaux | 2012 | Journal of Hepatology2012，，2： | 1 |
| 4 | Validation of an appropriate reference gene for normalization of reverse transcription–quantitative polymerase chain reaction data from rectal cancer biopsies显示文摘 | Alexandre Ho-Pun-Cheung Caroline Bascoul-Mollevi Eric Assenat Frédéric Bibeau Florence Boissière-Michot Dominic Cellier Marc Ychou Evelyne Lopez-Crapez | 2009 | Analytical Biochemistry2009，，2： | 1 |
| 5 | Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication显示文摘 | Stéphanie Faure Astrid Herrero Boris Jung Yohan Duny Jean-Pierre Daures Thibaut Mura Eric Assenat Micha?l Bismuth Hassan Bouyabrine Hélène Donnadieu-Rigole Francis Navarro Samir Jaber Dominique Larrey Georges-Philippe Pageaux | 2012 | Journal of Hepatology2012，，2： | 1 |
| 6 | Cyclin D1 Gene G870A Polymorphism Predicts Response to Neoadjuvant Radiotherapy and Prognosis in Rectal Cancer显示文摘 | Alexandre Ho-Pun-Cheung Eric Assenat Simon Thezenas Frédéric Bibeau Philippe Rouanet David Azria Dominic Cellier Jean Grenier Marc Ychou Pierre Senesse Evelyne Lopez-Crapez | 2007 | International Journal of Radiation Oncology, Biology, Physics2007，，4： | 1 |
| 7 | Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer显示文摘AIM:To investigate second-line chemotherapy in gemcitabine-pretreated patients with advanced or metastatic pancreatic cancer [(frequency,response,outcome,course of carbohydrate antigen 19-9 (CA 19-9)].METHODS:This retrospective study included all patients with advanced or metastatic pancreatic cancer (adenocarcinoma or carcinoma) treated with secondline chemotherapy in our center between 2000 and 2008.All patients received first-line chemotherapy with gemcitabine,and prior surgery or radiotherapy was permitted.We analyzed each chemotherapy protocol for second-line treatment,the number of cycles and the type of combination used.The primary endpoint was overall survival.Secondary endpoints included progression-free survival,response rate,grade 3-4 toxicity,dosage modifications and CA 19-9 course.RESULTS:A total of eighty patients (38%) underwenta second-line therapy among 206 patients who had initially received first-line treatment with a gemcitabine-based regimen.Median number of cycles was 4 (range:1-12) and the median duration of treatment was 2.6 mo (range:0.3-7.4).The overall disease control rate was 40.0%.The median overall survival and progression-free survival from the start of second-line therapy were 5.8 (95% CI:4.1-6.6) and 3.4 mo (95% CI:2.4-4.2),respectively.Toxicity was generally acceptable.Median overall survival of patients with a CA 19-9 level declining by more than 20% was 10.3 mo (95% CI:4.5-11.6) vs 5.2 mo (95% CI:4.0-6.4) for others (P=0.008).CONCLUSION:A large proportion of patients could benefit from second-line therapy,and CA 19-9 allows efficient treatment monitoring both in first and secondline chemotherapy. | Romain Altwegg Marc Ychou Vanessa Guillaumon Simon Thezenas Pierre Senesse Nicolas Flori Thibault Mazard Ludovic Caillo Stéphanie Faure Emmanuelle Samalin Eric Assenat | 2012 | World Journal of Gastroenterology2012，18，12： | 1 |
| 8 | Large,multifocal or portal vein-invading hepatocellular carcinoma(HCC)downstaged by Y90 using personalized dosimetry:safety,pathological results and outcomes after surgery显示文摘Background:Transarterial radioembolization(TARE)has recently been recognized as a bridging/downstaging therapy to surgery for early hepatocellular carcinomas(HCCs)with high rates of complete pathological necrosis(CPN)on liver explants.In patients with portal vein tumoral thrombus(PVTT),multifocal or large tumors,TARE has mainly a palliative role and surgery remains controversial in this poor-prognosis population.Personalized dosimetry recently proved to outperform standard dosimetry used in prior negative Y90 randomized-controlled trials.Methods:In this retrospective study,we evaluated safety,radiological and pathological response and outcomes in HCC patients with PVTT,multifocal or large tumors,who underwent surgery after downstaging using TARE with Y90-loaded glass microspheres with personalized dosimetry.Results:Between December 2015 and October 2021,18 unresectable patients(14/18 with PVTT)had surgery(16 resections,2 liver transplantations)6.2 months(range,2-14.6 months)after a single Y90 treatment.No 90-day mortality was reported.Objective modified response criteria in solid tumors(mRECIST)response were noted in all but one patient.Complete and extensive(50-99%)necrosis was observed in 36%and 45%of tumors,respectively.The post-treatment tumor-absorbed dose significantly differed depending on the extent of pathological necrosis(P=0.045).Median overall survival and progression-free survival(PFS)were respectively of 61.8 months[95%CI:31.4 months-not reached(NR)]and 49.3 months(95%CI:14 months-NR).PFS was longer in patients with complete imaging response[median NR(none recurred or died)vs.21.5 months(95%CI:10.1 months-NR),P<0.001]and in those with complete pathological response[median NR vs.22.5 months(95%CI:10.1 months-NR),P<0.001].Conclusions:Y90 TARE using personalized dosimetry can provide high rates of imaging and pathological response in patients with PVTT,large or multifocal HCC.Subsequent surgery is safe and leads to outcomes far exceeding expectations in an otherwise poor prognosis population with no chance for cure. | Mohamad Azhar Meerun Carole Allimant Benjamin Rivière Astrid Herrero Fabrizio Panaro Eric Assenat Christophe Cassinotto Denis Mariano-Goulart Boris Guiu | 2023 | Hepatobiliary Surgery and Nutrition2023，12，3： | 0 |
| 9 | Is chronic hepatitis C virus infection a risk factor for breast cancer?显示文摘AIM:To evaluate the prevalence of breast tumors in adult females with chronic hepatitis C virus(HCV) infection.METHODS:Prospective,single-center study,based on female outpatients consulting in a liver unit,for 1 year.The study group included females with present and/or past history of chronic infection by HCV.Patients with spontaneous recovery were excluded.Chronic hepatitis had been proved by liver biopsy in the majority of cases and/or biological markers of inflammation and fibrosis.The control group included female patients with other well documented chronic liver diseases:chronic hepatitis B,alcoholic liver disease,autoimmune hepatitis,hemochromatosis,non alcoholic liver disease,chronic cholangitis.Participating patients were prospectively questioned during consultation about past breast history and follow-up by mammography.RESULTS:Breast carcinoma was recorded in 17/294 patients with HCV infection(5.8%,95% CI:3.1-8.4) vs 5/107 control patients(4.7%,95% CI:0.67-8.67).Benign tumors of the breast(mastosis,nodules,cysts) were recorded in 75/294 patients with HCV infection(25.5%,95% CI:20.5-30.5) vs 21/107(19.6%,95% CI:12.1-27.1) in the control group.No lesion was noted in 202 patients with HCV(68.7%,95% CI:63.4-74) vs 81 control patients(75.7%,95% CI:67.6-83.8).Despite a trend to an increased prevalence in the group with HCV infection,the difference was not significant compared to the control group(P=NS).In patients over 40 years,the results were,respectively,as follows:breast cancer associated with HCV:17/266 patients(6.3%,95% CI:3.4-9.3) vs 5/95 patients(5.2%,95% CI:0.7-9.7) in the control group;benign breast tumors:72/266 patients with HCV infection(27%,95% CI:21.7-32.4) vs 18/95 patients(18.9%,95% CI:11-26.8) in the control group;no breast lesion 177/266(66.5%,95% CI:60.9-72.2) in patients with HCV infection vs 72/95(75.7%,95% CI:67.1-84.4) in the control group.The differences were not significant(P=NS).CONCLUSION:These results suggest that chronic HCV infection is not a strong promoter of breast carcinoma in adult females of any age. | Dominique Larrey Marie-Cécile Bozonnat Ihab Kain Georges-Philippe Pageaux Eric Assenat | 2010 | World Journal of Gastroenterology2010，16，29： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员